Cannabinoid-based Possible Treatment for Parkinson’s, EHP-102, Seen as Superior to New Molecules in Early Test

Cannabinoid-based Possible Treatment for Parkinson’s, EHP-102, Seen as Superior to New Molecules in Early Test
Emerald Health Pharmaceuticals announced that two of its cannabinoid-derived candidates — CBGA-Q and CBGA-Q-Na Salt — showed anti-inflammatory and neuroprotective effects in a mouse model of Parkinson’s disease. However, these benefits were not superior to those obtained from treatment with the company’s already patented EHP-102 compound. The findings, “Comparison of the neuroprotective activity of cannabigerol derivatives in Huntington’s and Parkinson’s ... read more
Source: Parkinson’s News TodayPublished on 2019-07-09By Catarina Silva